Organovo Announces Release Date for Fiscal Second-Quarter 2018 Financial Results
October 19 2017 - 8:05AM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a
conference call on Thursday, November 9, 2017 at 5:00 p.m. Eastern
Time (ET) to discuss the Company's fiscal second-quarter 2018
financial results. In advance of the call on November 9,
2017, Organovo will issue its fiscal second-quarter 2018 earnings
press release, which will be available at
http://www.organovo.com. To participate in the
teleconference, callers can dial the following numbers:
1-888-317-6003 (toll-free, U.S. callers only)
1-412-317-6061 (from outside the U.S.)
Conference Call ID: 4644999
To help ensure the conference call begins in a timely manner,
please dial in five minutes prior to the scheduled start
time. The conference call will also be simultaneously webcast
at http://www.organovo.com.
For those unable to participate in the live call, a replay of
the call will be available toll-free until November 16, 2017 at
1-877-344-7529 (U.S. callers only) or at 1-412-317-0088 (callers
outside the U.S.). The passcode for the replay is:
10111988. An archived replay of the webcast will also be
available at http://www.organovo.com.
About Organovo Holdings, Inc.Organovo designs
and creates functional, three-dimensional human tissues for use in
drug discovery, clinical development, and therapeutic
applications. The Company develops 3D human tissue systems
through internal research programs and in collaboration with
pharmaceutical, academic and other partners. Organovo's 3D
human tissues have the potential to transform the drug discovery
process, enabling treatments to be developed more effectively and
with greater relevance to performance in human trials and
commercialization. The Company’s ExVive™ Human Liver and
Kidney Tissues are used in high-value drug profiling, including
compound screening in disease models, toxicology, target and marker
discovery/validation, and other drug testing. The Company is
also advancing a preclinical program to develop liver therapeutic
tissues for critical unmet medical needs, including certain
life-threatening pediatric diseases. In addition to numerous
scientific publications, the Company’s technology has been featured
in The Wall Street Journal, Time Magazine, The Economist, Forbes,
and numerous other media outlets. Organovo is changing the
shape of life science research and transforming medical care.
Learn more at www.organovo.com.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. Forward-looking statements include, but are
not limited to, statements regarding the Company’s preliminary
revenue results for the second quarter of fiscal year 2018, the
potential for one or more customer’s electing to implement the
Company’s platform for larger routine use applications by the end
of fiscal 2018, the expected costs, timing and operational benefits
of the Company’s restructuring plan and the financial impact of the
Company’s restructuring plan on its future operating costs and
financial results. The Company’s reported revenue results for
the second quarter of fiscal year 2018 are preliminary, and subject
to adjustments in the ongoing review by the Company and its
external auditors. The factors that could cause the Company's
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products and services based on its technology; the
expected benefits and efficacy of the Company's products, services
and technology; the Company’s ability to successfully complete
studies and provide the technical information required to support
market acceptance of its products, services and technology, on a
timely basis or at all; the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies, including its use of third party distributors; the
Company's ability to successfully complete the contracts and
recognize the revenue represented by the contracts included in its
previously reported total contract bookings and secure additional
contracted collaborative relationships; the final results of the
Company's preclinical studies may be different from the Company's
studies or interim preclinical data results and may not support
further clinical development of its therapeutic tissues; the
Company may not successfully complete the required preclinical and
clinical trials required to obtain regulatory approval for its
therapeutic tissues on a timely basis or at all; the risk of
further adjustments to the Company’s preliminary revenue results
for the second quarter of fiscal 2018; the Company’s ability to
control the costs and to achieve the expected operational benefits
and long- term cost savings of its restructuring plan; and the
Company’s ability to meet its fiscal year 2018 outlook. These and
other factors are identified and described in more detail in the
Company's filings with the SEC, including its Annual Report on Form
10-K filed with the SEC on June 7, 2017. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that the Company may issue in the future. Except as required by
applicable law, including the securities laws of the United States,
the Company does not intend to update any of the forward-looking
statements to conform these statements to reflect actual results,
later events or circumstances or to reflect the occurrence of
unanticipated events.
Investor Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Press Contact:
Jessica Yingling
Little Dog Communications
+1 (858) 480-2411
jessica@litldog.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Sep 2023 to Sep 2024